Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29019950 | 0.87 | MEN1 (0.51) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL69492 | 0.87 | MEN1 (0.58) | ALPLMEN1KMT2APOLBMAPT | |
| SCHEMBL1413993 | 0.86 | HCAR2 (0.55) | ALPLMEN1KMT2APOLBMAPT | |
| SCHEMBL1413913 | 0.86 | NPC1 (0.55) | CA12ALPLMEN1KMT2APOLB | |
| SCHEMBL70800 | 0.86 | RAB9A (0.55) | CA12ALPLMEN1KMT2APOLB | |
| SCHEMBL1413865 | 0.86 | ALPL (0.53) | ALPLMEN1KMT2APOLBMAPT | |
| SCHEMBL19996893 | 0.86 | MEN1 (0.50) | CA12ALPLMEN1KMT2APOLB | |
| SCHEMBL1413926 | 0.86 | MEN1 (0.54) | MEN1KMT2APOLBMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL1221862 | 0.85 | MEN1 (0.57) | ALPLMEN1KMT2APOLBMAPT | |
| SCHEMBL3519352 | 0.84 | MEN1 (0.55) | MEN1KMT2APOLBMAPTHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | claimed |
| WO-2010075356-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-01 | — | — | WO | claimed |
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | claimed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | claimed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | claimed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3566055-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Yumanity Therapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| WO-2018129403-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS (US) | 2018-07-12 | — | — | WO | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| WO-2010075356-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-24 | — | — | US | disclosed |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009143150-A2 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160323-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | CA12 4790/4885ALPL 3494/4885MEN1 4883/4885 |
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | CA12 755/4885ALPL 3373/4885MEN1 2780/4885 |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | CA12 4836/4885ALPL 3708/4885MEN1 4884/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | CA12 755/4885ALPL 3373/4885MEN1 2780/4885 |
| US-20100016313-A1 | INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF | ALPI, SI, FABP2 | CA12 1444/4885ALPL 5/4885MEN1 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.